Ocugen (OCGN) Company Report

Ocugen, Inc. announced the closing of an underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share on January 23, 2026.
The offering resulted in net proceeds of $20.85 million for the company, after deducting commissions and estimated offering expenses.
Ocugen plans to use the proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses, expecting this to extend its cash runway into the fourth quarter of 2026.

Jan 23, 2026, 1:12 PM

8-K

Ocugen Announces Closing of Registered Direct Offering

OCGN

Ocugen, Inc. closed an underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share.
The offering resulted in net proceeds of $20.85 million for Ocugen, after deducting commissions and estimated offering expenses, with financing led by RTW Investments.
The company intends to use the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
These net proceeds are anticipated to extend Ocugen's cash runway into the fourth quarter of 2026.

Jan 23, 2026, 1:00 PM

Press Release

Ocugen prices common stock offering

OCGN

Ocugen, Inc. announced the pricing of an underwritten offering of 15,000,000 shares of its common stock at $1.50 per share.
The offering is expected to generate gross proceeds of $22.5 million and net proceeds of approximately $20.8 million.
The net proceeds will be used for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
The offering is anticipated to close on or about January 22, 2026, and is being led by RTW Investments.

Jan 21, 2026, 10:29 PM

8-K

Ocugen Prices $22.5 Million Common Stock Offering

OCGN

Ocugen, Inc. announced the pricing of an underwritten offering of 15,000,000 shares of its common stock at $1.50 per share.
The offering is expected to generate gross proceeds of $22.5 million and is anticipated to close on or about January 22, 2026.
The net proceeds from the offering are intended for general corporate purposes, capital expenditures, working capital, and general administrative expenses.
RTW Investments is leading the financing for this offering.

Jan 21, 2026, 1:32 PM

Press Release

Ocugen Announces Positive Preliminary Phase 2 Data for OCU410 Gene Therapy

OCGN

Product Launch

New Projects/Investments

Ocugen announced positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial for OCU410, a modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
The Phase 2 trial demonstrated a 46% lesion growth reduction in treated patients (medium + high dose) compared to control at 12 months.
No OCU410-related serious adverse events have been reported across Phase 1 and Phase 2 clinical trials to date.
Ocugen plans to initiate Phase 3 for OCU410 in 2026 and targets a Biologics License Application (BLA) filing in 2028.

Jan 15, 2026, 1:31 PM

8-K

Ocugen Presents Positive OCU410 Phase 2 Interim Results for Geographic Atrophy

OCGN

New Projects/Investments

Guidance Update

Ocugen presented interim data from the OCU410 phase 2 ARMADA clinical trial for geographic atrophy (GA), demonstrating a 46% statistically significant reduction in GA lesion growth at 12 months compared to control eyes (P-value = 0.015).
The OCU410 gene therapy exhibited a clean safety profile, with no serious adverse events reported to date.
For patients with larger baseline GA lesions (equal to or greater than 7.5 square), OCU410 achieved a 57% reduction in lesion growth. Additionally, up to 50% of treated patients experienced greater than 50% lesion size reduction.
Ocugen plans to initiate its phase 3 portal trial later in 2026, targeting completion of phase 3 enrollment in 2027, and anticipates generating top-line phase 3 data and submitting a Biologics License Application (BLA) to the FDA in 2028.

Jan 15, 2026, 1:30 PM

Transcript

Ocugen Provides OCU410 Clinical Updates for Geographic Atrophy

OCGN

New Projects/Investments

Ocugen's OCU410 is a one-time gene therapy for geographic atrophy (GA) designed to address four pathways implicated in GA progression, offering a potential durable benefit compared to existing therapies requiring frequent injections.
The Phase 1 ARMADA trial demonstrated a safe and tolerable profile for OCU410, showing a 20.2% reduction in GA lesion growth at 12 months compared to untreated fellow eyes and 60% slower loss of the ellipsoid zone.
Interim Phase 2 results showed a clean safety profile and a statistically significant 46% reduction in GA lesion growth at 12 months in treated eyes compared to control eyes (p=0.015).
In the Phase 2 trial, the medium dose group achieved a 54% reduction in lesion growth, while the high-dose group showed a 36% reduction compared to control. Up to 50% of treated patients achieved greater than 50% lesion size reduction.
OCU410's 46% reduction at 12 months compares favorably to published data for approved therapies like Izervay, which showed approximately a 22% reduction at 24 months, though direct comparisons are limited due to different trial contexts. The company plans to provide a full data set later this quarter, initiate its Phase 3 trial later this year, target completion of Phase 3 enrollment in 2027, and anticipate top-line Phase 3 data and BLA submission in 2028.

Jan 15, 2026, 1:30 PM

Transcript

Ocugen provides OCU410 clinical development update

OCGN

New Projects/Investments

Guidance Update

Ocugen's OCU410 program for geographic atrophy (GA) reported a 46% statistically significant reduction in GA lesion growth at 12 months in its Phase II interim analysis, with a 54% reduction for the medium dose and 57% reduction in patients with larger lesions.
The gene therapy demonstrated a clean safety profile with no serious adverse events, positioning it as a potential one-time administration solution for GA, unlike existing therapies requiring frequent injections.
Ocugen plans to initiate its Phase III pivotal trial later this year, with anticipated top-line Phase III data and BLA submission to the FDA in 2028.
OCU410 targets a significant unmet medical need for 2-3 million GA patients in the U.S. and E.U., offering a multi-pathway approach that compares favorably to approved therapies which showed approximately 22% reduction in lesion growth at 24 months.

Jan 15, 2026, 1:30 PM

Transcript

Ocugen Announces Positive Preliminary Phase 2 Data for OCU410 Gene Therapy

OCGN

New Projects/Investments

Ocugen announced positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial evaluating OCU410, a novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
Key findings from Phase 2 include a 46% lesion growth reduction (medium + high dose vs. control) at 12 months, with the medium dose achieving a 54% lesion reduction.
There have been no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date.
Ocugen plans to report full Phase 2 data later this quarter, initiate Phase 3 in 2026, and remains on track for a Biologics License Application (BLA) filing in 2028.

Jan 15, 2026, 1:15 PM

Press Release

Ocugen Publishes Positive Phase 1 Trial Results for OCU410ST Gene Therapy

OCGN

Product Launch

New Projects/Investments

Ocugen announced the publication of positive Phase 1 GARDian1 trial results for its OCU410ST modifier gene therapy for Stargardt disease in the peer-reviewed journal Nature Eye.
The trial demonstrated a favorable safety and tolerability profile and clinically meaningful functional and structural benefits, including a 54% reduction in atrophic lesion growth and 100% of treated eyes stabilizing or improving visual acuity.
These positive results support the ongoing Phase 2/3 GARDian3 trial, with enrollment anticipated to complete in the first quarter of 2026.
Ocugen is positioned for a Biologics License Application (BLA) filing in the first half of 2027 for OCU410ST.